Abiopharma

🔍 Vandervoort Adam C (Executive)

Company: Teladoc Health, Inc. (TDOC)

Report Date: 2025-08-29

Detailed Transactions and Holdings:

• Acquired 1,505 shares of Common Stock (Direct)
  Date: 2025-08-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 71,278.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 4,418 shares of Common Stock (Direct)
  Date: 2025-08-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 75,696.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 5,350 shares of Common Stock (Direct)
  Date: 2025-08-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 81,046.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 5,867 shares of Common Stock at $7.585 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 75,179.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 1,505 shares of Performance Stock Units (Derivative)
  Date: 2025-08-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,015.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Sold 4,418 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,836.00 | transaction_form_type: 4 | Footnotes: F2, F5, F5
• Sold 5,350 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,100.00 | transaction_form_type: 4 | Footnotes: F2, F6, F6

Footnotes:

• F1: Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
• F2: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
• F3: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
• F4: The performance stock units vest as to one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
• F5: On March 3, 2023, the reporting person was granted 53,013 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
• F6: One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.